Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
Abstract As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepati...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-020-66440-9 |